Cargando…

The Serial Engagement Model 17 Years After: From TCR Triggering to Immunotherapy

More than 15 years ago the serial engagement model was proposed as an attempt to solve the low affinity/high sensitivity paradox of TCR antigen recognition. Since then, the model has undergone ups and downs marked by the technical and conceptual advancements made in the field of T lymphocyte activat...

Descripción completa

Detalles Bibliográficos
Autor principal: Valitutti, Salvatore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3428561/
https://www.ncbi.nlm.nih.gov/pubmed/22973273
http://dx.doi.org/10.3389/fimmu.2012.00272
_version_ 1782241703411843072
author Valitutti, Salvatore
author_facet Valitutti, Salvatore
author_sort Valitutti, Salvatore
collection PubMed
description More than 15 years ago the serial engagement model was proposed as an attempt to solve the low affinity/high sensitivity paradox of TCR antigen recognition. Since then, the model has undergone ups and downs marked by the technical and conceptual advancements made in the field of T lymphocyte activation. Here, I describe the development of the model and survey recent literature providing evidence either for or against the idea that serial TCR/pMHC engagement might contribute to T lymphocyte activation. I also discuss how the concept of serial TCR engagement might be useful in the design of immunotherapeutic approaches aimed at potentiating T lymphocyte responses in vivo.
format Online
Article
Text
id pubmed-3428561
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Frontiers Research Foundation
record_format MEDLINE/PubMed
spelling pubmed-34285612012-09-12 The Serial Engagement Model 17 Years After: From TCR Triggering to Immunotherapy Valitutti, Salvatore Front Immunol Immunology More than 15 years ago the serial engagement model was proposed as an attempt to solve the low affinity/high sensitivity paradox of TCR antigen recognition. Since then, the model has undergone ups and downs marked by the technical and conceptual advancements made in the field of T lymphocyte activation. Here, I describe the development of the model and survey recent literature providing evidence either for or against the idea that serial TCR/pMHC engagement might contribute to T lymphocyte activation. I also discuss how the concept of serial TCR engagement might be useful in the design of immunotherapeutic approaches aimed at potentiating T lymphocyte responses in vivo. Frontiers Research Foundation 2012-08-28 /pmc/articles/PMC3428561/ /pubmed/22973273 http://dx.doi.org/10.3389/fimmu.2012.00272 Text en Copyright © 2012 Valitutti. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
spellingShingle Immunology
Valitutti, Salvatore
The Serial Engagement Model 17 Years After: From TCR Triggering to Immunotherapy
title The Serial Engagement Model 17 Years After: From TCR Triggering to Immunotherapy
title_full The Serial Engagement Model 17 Years After: From TCR Triggering to Immunotherapy
title_fullStr The Serial Engagement Model 17 Years After: From TCR Triggering to Immunotherapy
title_full_unstemmed The Serial Engagement Model 17 Years After: From TCR Triggering to Immunotherapy
title_short The Serial Engagement Model 17 Years After: From TCR Triggering to Immunotherapy
title_sort serial engagement model 17 years after: from tcr triggering to immunotherapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3428561/
https://www.ncbi.nlm.nih.gov/pubmed/22973273
http://dx.doi.org/10.3389/fimmu.2012.00272
work_keys_str_mv AT valituttisalvatore theserialengagementmodel17yearsafterfromtcrtriggeringtoimmunotherapy
AT valituttisalvatore serialengagementmodel17yearsafterfromtcrtriggeringtoimmunotherapy